Xzōm
Xzōm provides a near-patient diagnostic platform that uses proprietary Alternating Current Electrokinetics (ACE) technology to isolate and analyze exosome biomarkers from a minimal blood sample in under 30 minutes. The low-cost, easy-to-use instrument is initially focused on early pancreatic cancer detection, with a pipeline of additional oncology applications planned.
- Healthcare Technology
- Medical Devices
- Biotechnology
- Hardware
- Digital Health
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Current diagnostic methods often require sending samples to large reference laboratories, leaving patients waiting for days or weeks for results. This delayed turnaround is particularly harmful for life-threatening diseases where early detection is critical to treatment outcomes, yet many patients lack access to timely or sensitive screening tools.
Solution
Xzōm provides a near-patient diagnostic platform that uses proprietary Alternating Current Electrokinetics (ACE) technology to rapidly isolate, analyze, and quantify exosome biomarkers from a minimal blood sample—with results in less than 30 minutes. The low-cost, easy-to-use instrument is designed for use near the patient, eliminating the need for specialized laboratory infrastructure and enabling earlier intervention. The platform leverages exosomes, which are continuously secreted by living cells and carry DNA, RNA, proteins, and metabolites, offering a richer and more dynamic source of biological information than cell-free DNA. Xzōm is initially focusing on pancreatic cancer detection, with a pipeline of additional oncology and disease applications planned.
Target Audience
Primary customers are physicians, clinicians, and healthcare providers seeking point-of-care diagnostic solutions for oncology and other critical disease areas, as well as communities and clinical settings without immediate access to major medical or cancer centers.
Features
- Proprietary ACE (Alternating Current Electrokinetics) technology for rapid exosome isolation and analysis from unprocessed plasma
- Minimal sample volume requirement of less than 80 µL, enabling near-patient testing
- End-to-end workflow with results in under 30 minutes: load sample, activate ACE, fluidic wash
- One platform supporting multiple diagnostic applications, including early detection and ongoing patient monitoring
- Exosomes are 1,000x+ more plentiful than cell-free/circulating tumor DNA, providing richer biomarker data from smaller samples
- Backed by 15 years of R&D, 58 worldwide patents (23 US patents), and 19 peer-reviewed publications